Dóra Bihary

Dóra Bihary

Auto-generated profile, based on publicly available information

Dóra Bihary

Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4, Budapest H-1089, Hungary; Center for Pharmacology and Drug Research & Development, Semmelweis University, Nagyvárad tér 4, Budapest H-1089, Hungary

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
IOIoana Olan
Ioana Olan
APAled J Parry
Aled J Parry
SSStefan Schoenfelder
Stefan Schoenfelder
MNMasako Narita
Masako Narita
YIYoko Ito
Yoko Ito
MNMasashi Narita
Masashi Narita
Senescence is a state of stable proliferative arrest, generally accompanied by the senescence-associated secretory phenotype, which modulates tissue homeostasis. Enhancer-promoter interactions, facilitated by chromatin loops, play a key role in gene regulation but their relevance in senescence remains elusive. Here, we use Hi-C to show that oncogenic RAS-induced senescence in human diploid fibroblasts is accompanied by extensive enhancer-promoter rewiring, which is closely connected with dynamic cohesin binding to the genome. We find de novo cohesin peaks often at the 3′ end of a subset of active genes. RAS-induced de novo cohesin peaks are transcription-dependent and enriched for senescence-associated genes, exemplified by IL1B, where de novo cohesin binding is involved in new loop formation. Similar IL1B induction with de novo cohesin appearance and new loop formation are observed in terminally differentiated macrophages, but not TNFα-treated cells. These results suggest that RAS-induced senescence represents a cell fate determination-like process characterised by a unique gene expression profile and 3D genome folding signature, mediated in part through cohesin redistribution on chromatin.

20 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLaura D. Martens
Laura D. Martens
OFOisín Faust
Oisín Faust
LPLiviu Pirvan
Liviu Pirvan
DBDóra Bihary
Dóra Bihary
SSShamith A. Samarajiwa
Shamith A. Samarajiwa
Chromosome conformation capture methods such as Hi-C enables mapping of genome-wide chromatin interactions and is a promising technology to understand the role of spatial chromatin organisation in gene regulation. However, the generation and analysis of these data sets at high resolutions remain technically challenging and costly. We developed a machine and deep learning approach to predict functionally important, highly interacting chromatin regions (HICR) and topologically associated domain (TAD) boundaries independent of Hi-C data in both normal physiological states and pathological conditions such as cancer. This approach utilises gradient boosted trees and convolutional neural networks trained on both Hi-C and histone modification epigenomic data from three different cell types. Given only epigenomic modification data these models are able to predict chromatin interactions and TAD boundaries with high accuracy. We demonstrate that our models are transferable across cell types, indicating that combinatorial histone mark signatures may be universal predictors for highly interacting chromatin regions and spatial chromatin architecture elements.

14 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAnna M. Sozanska
Anna M. Sozanska
CFCharles Fletcher
Charles Fletcher
DBDóra Bihary
Dóra Bihary
SSShamith A. Samarajiwa
Shamith A. Samarajiwa
A bstract: More than three decades ago, the microarray revolution brought about high-throughput data generation capability to biology and medicine. Subsequently, the emergence of massively parallel sequencing technologies led to many big-data initiatives such as the human genome project and the encyclopedia of DNA elements (ENCODE) project. These, in combination with cheaper, faster massively parallel DNA sequencing capabilities, have democratised multi-omic (genomic, transcriptomic, translatomic and epigenomic) data generation leading to a data deluge in bio-medicine. While some of these data-sets are trapped in inaccessible silos, the vast majority of these data-sets are stored in public data resources and controlled access data repositories, enabling their wider use (or misuse). Currently, most peer reviewed publications require the deposition of the data-set associated with a study under consideration in one of these public data repositories. However, clunky and difficult to use interfaces, subpar or incomplete annotation prevent discovering, searching and filtering of these multi-omic data and hinder their re-purposing in other use cases. In addition, the proliferation of multitude of different data repositories, with partially redundant storage of similar data are yet another obstacle to their continued usefulness. Similarly, interfaces where annotation is spread across multiple web pages, use of accession identifiers with ambiguous and multiple interpretations and lack of good curation make these data-sets difficult to use. We have produced SpiderSeqR, an R package, whose main features include the integration between NCBI GEO and SRA databases, enabling an integrated unified search of SRA and GEO data-sets and associated annotations, conversion between database accessions, as well as convenient filtering of results and saving past queries for future use. All of the above features aim to promote data reuse to facilitate making new discoveries and maximising the potential of existing data-sets. Availability: https://github.com/ss-lab-cancerunit/SpiderSeqR

29 November 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
BKBernadett Kiss
Bernadett Kiss
RNRegina Norma Nagy
Regina Norma Nagy
GBGábor B. Brenner
Gábor B. Brenner
BVBarnabás Váradi
Barnabás Váradi
DBDóra Bihary
Dóra Bihary
AGAnikó Görbe
Anikó Görbe
Hidden cardiotoxicity is defined as cardiotoxicity of a drug that manifests only in the diseased heart. We have previously shown that the proarrhythmic hidden cardiotoxic properties of a model drug, the selective cyclooxygenase-2 inhibitor rofecoxib, can be revealed in preclinical models of ischemia/reperfusion injury. As metabolic comorbidities, such as hypercholesterolemia (HC), may exacerbate hidden cardiotoxicity, we aimed to investigate the hidden cardiotoxic effects of the model drug, rofecoxib, in the presence of hypercholesterolemia. Rats were fed a high-cholesterol diet for 12 weeks and treated with 5.12 mg/kg rofecoxib. Four weeks of rofecoxib treatment surprisingly improved HC-induced mild cardiac dysfunction by restoring end-diastolic pressure, stroke work, and mechanical efficiency. Then, RNA sequencing revealed that the expression of 28 miRNAs and 300 genes was significantly altered in the HC-fed group. The HC-induced expression changes of miR-27a-5p and miR-30d-5p were reversed by rofecoxib treatment. Cdc42ep4, Cox5, and Cxcl9 genes were also counter-regulated following rofecoxib treatment compared to HC-induced changes. This is the first demonstration that rofecoxib improves HC-induced cardiac dysfunction, with the mechanism involving changes in the gene expression profile, including some key regulators of rofecoxib action.